Capsaicin: A Comprehensive Encyclopedic Reference
1. Identity: Botanical and Chemical Names, Natural Source, and Common Forms
Botanical and Chemical Identity
The chemical compound capsaicin (8-methyl-N-vanillyl-6-nonenamide) is the active component of chili peppers, which are plants belonging to the genus Capsicum. It is also formally designated by the IUPAC as N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-trans-6-enamide. Capsaicin is a widely recognized member of the vanilloid family and has drawn significant attention in the scientific community because of its broad spectrum of pharmacological effects and diverse bioactive characteristics. The CAS registry number is 404-86-4, and capsaicin is classified as a phenylpropanoid compound.
Capsaicin is practically insoluble in water, but freely soluble in alcohol, ether, benzene, and chloroform. Capsaicin is an alkaloid in the vanilloid family, fat-soluble and relatively stable under moderate heat. It concentrates mainly in the placental tissue (the white pith) of Capsicum species.
Natural Source and Occurrence
Capsaicin occurs naturally in many pepper plants related to Capsicum annuum, which grows indigenously in tropical America. The concentration of capsaicin is impacted by the maturity of the chili peppers; dried fruits possess 7–10 times the amount of capsaicin as fresh ones. Overall, the capsaicin content in chili peppers ranges from 0.1% to 1% by weight. The only variety of Capsicum that lacks capsaicin is the sweet pepper.
Capsaicin belongs to a broader family of related compounds known as capsaicinoids. The most commonly occurring capsaicinoids are capsaicin (69%), dihydrocapsaicin (22%), nordihydrocapsaicin (7%), homocapsaicin (1%), and homodihydrocapsaicin (1%). Capsaicin and dihydrocapsaicin (both 16.0 million SHU) are the most pungent capsaicinoids.
Discovery and Chemical History
In 1816, Christian Friedrich Bucholz first carried out the purification of capsaicin, obtaining an incompletely purified form to which he gave the name "capsaicin." In 1876, John Clough Thresh further purified it to obtain pure capsaicin. In 1919, Nelson identified the capsaicin structure. In 1930, E. Späth and S.F. Darling used a chemical synthesis method for the first time to successfully synthesize capsaicin.
Common Preparations and Dosage Forms
Capsaicin is administered in many forms such as low-concentration creams, lotions, patches, intradermal injections, oral formulations, subcutaneous injections, films, microemulsions, liposomes, and nanotechnology-derived drug delivery systems. Over-the-counter preparations include topical creams at concentrations of 0.025%, 0.033%, 0.035%, 0.075%, 0.1%, and 0.25%, as well as topical films, liquids, and lotion forms at lower concentrations, and prescription-strength transdermal patches at 8% concentration. Ground peppers may be further refined to the oleoresin, which is a reddish-brown liquid with little odor. When extracted from plants, the capsicum oleoresin may contain many volatile compounds in addition to capsaicin.
2. Traditional and Historical Use
Pre-Columbian Americas
Archaeological evidence suggests that chili peppers were cultivated and consumed as early as 7500 BCE in Mexico. The Aztecs and Mayans used them not only for food but also for medicinal purposes, treating a variety of ailments. Ancient Aztecs and Mayans prized the heat not just for flavor but as a preservative and even a mild antiseptic when applied topically.
Spread to the Old World
When Christopher Columbus encountered chili peppers in the Caribbean in 1492, he brought them back to Europe, where they quickly spread to Africa and Asia. This introduction led to the integration of chili peppers into diverse culinary traditions worldwide, making capsaicin a global phenomenon. Traditional culinary practices across India, Thailand, Mexico, and China all revolve around capsaicin-rich foods.
Early Medicinal Use and Counter-Irritant Tradition
Since its discovery, capsaicin has been used as a homeopathic remedy to treat burning pain using the concept of "treating like with like" or counter-irritant. The first reports of its pain-relieving properties appeared in the mid-1850s as a recommendation to use it for parts of the body that burn or itch. Since ancient times, capsaicin has been used as a homeopathic remedy to treat a wide range of pathological conditions, according to the concept of "treating like with like" or "fight fire with fire."
Historically, chili peppers were also used to preserve food. Their antimicrobial properties help prevent spoilage, making them valuable in regions without refrigeration.
3. Key Constituents and Mechanisms of Action
The Capsaicinoid Family
In the 1960s, Japanese investigators identified additional substances from Capsicum extracts with similar chemical and pharmacological properties that were termed "capsaicinoids." This family of chemical analogues includes both natural (homodihydrocapsaicin, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin, and capsaicin) and synthetic (nonivamide) members. Capsaicin and dihydrocapsaicin are the most potent active substances in capsicum.
Biosynthesis
The general biosynthetic pathway of capsaicin and other capsaicinoids was elucidated in the 1960s by Bennett, Kirby, Leete, and Louden. Radiolabeling studies identified phenylalanine and valine as the precursors to capsaicin. Enzymes of the phenylpropanoid pathway, including phenylalanine ammonia lyase (PAL), cinnamate 4-hydroxylase (C4H), and caffeic acid O-methyltransferase (COMT), and their function in capsaicinoid biosynthesis were identified later.
Primary Mechanism: TRPV1 Receptor Activation
The molecular site of action for capsaicin is the transient receptor potential cation channel vanilloid subfamily member 1 (TRPV1), which is expressed by polymodal capsaicin-sensitive nociceptive neurons in their central branches and peripheral terminals, and also in trigeminal ganglion neurons, vagal afferents in jugular and nodose ganglion neurons.
Capsaicin selectively activates TRPV1, a Ca²⁺-permeable cationic ion channel that is enriched in the terminals of certain nociceptors. Activation is followed by a prolonged decreased response to noxious stimuli. In neurons, cation (Ca²⁺) influx through TRPV1 causes membrane depolarization, leading to the activation of voltage-gated sodium channels and the generation of an action potential.
Unique among natural irritants, capsaicin initially excites neurons but then "calms" them into long-lasting non-responsiveness. When TRPV1 is continuously activated through prolonged exposure to an agonist such as capsaicin, excessive calcium enters the nerve fiber, initiating processes that result in long-term yet reversible impairment of nociceptor function. This is believed to be the mechanism by which application of capsaicin provides relief from pain.
Neuropeptide Release
Activation of sensory nerves by capsaicin evokes the local release of the neuropeptides calcitonin gene-related peptide (CGRP), the tachykinins substance P (SP) and neurokinin A (NKA), and somatostatin, not only into the spinal cord but also in the periphery. These neuropeptides result in local tissue vascular responses, increased microvascular permeability, plasma extravasation, and neurogenic inflammation.
TRPV1 in Broader Physiology
Broadly speaking, TRPV1 has been linked to thermos-sensation (heat), autonomic thermoregulation, nociception, food intake regulation, and multiple functions in the gastrointestinal (GI) tract. Increasing evidence indicates that TRPV1 plays a critical role in the regulation of metabolic health for the whole body, including body weight, glucose and lipid metabolism, and the cardiovascular system. TRPV1 has been deemed as a potential target for the prevention of obesity due to its effect on energy metabolism and balance.
Ecological Role of Capsaicin
In birds, the TRPV1 channel does not respond to capsaicin or related chemicals, but mammalian TRPV1 is very sensitive to it. This is advantageous to the plant, as chili pepper seeds consumed by birds pass through the digestive tract and can germinate later, whereas mammals have molar teeth that destroy such seeds and prevent them from germinating. Thus, natural selection may have led to increasing capsaicin production because it makes the plant less likely to be eaten by animals that do not help it disperse.
4. Scientific Evidence by Area of Use
4.1 Neuropathic Pain: High-Concentration Topical Patch (8%)
The most robust clinical evidence for capsaicin pertains to its use as a high-concentration (8%) topical patch (marketed as Qutenza) for neuropathic pain. Qutenza received FDA approval in 2009 for the management of neuropathic pain associated with postherpetic neuralgia, and subsequently received a second FDA approval for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults.
A multicenter, double-blind study included 402 participants with at least a six-month history of postherpetic neuralgia who were randomized to receive a one-time 60-minute application of the 8% capsaicin-containing Qutenza patch (206 patients) or a low-concentration 0.04% capsaicin control patch (196 patients). The primary efficacy endpoint was percentage change in numeric pain rating scale (NPRS) score from baseline to weeks two to eight. Patients were followed to week 12. Results showed a significantly greater reduction in pain between weeks two and eight in patients receiving the Qutenza patch compared to controls. The mean changes in the NPRS scores from baseline to week eight were −29.6% versus −19.9% for the Qutenza and control groups, respectively.
Two pivotal clinical trials compared Qutenza to a control patch (0.04% capsaicin) in postherpetic neuralgia. The primary endpoint of both trials was the reduction in NPRS score. Qutenza reduced pain from baseline to weeks 2 to 8 (29.6% and 32% reductions) compared to control (19.9% and 24.4% reductions; P ≤ .01). The improvement in NPRS scores persisted, with score reductions greater with Qutenza (29.9% and 32.3% reductions) compared to control (20.4% and 25% reductions; P ≤ .03) for the period 2 to 12 weeks.
A meta-analysis further confirmed these findings: the meta-analysis combined individual patient data from randomized, controlled studies of Qutenza in peripheral neuropathic pain — 1,458 subjects treated with approved doses of Qutenza or control patches, including 1,120 with postherpetic neuralgia and 338 with HIV-associated neuropathy, across seven studies using the high-dose 8% capsaicin patch and a 0.04% low-dose control patch. In a meta-analysis examining 2,057 persons with postherpetic neuralgia and HIV-associated neuropathy, the proportion of responders with relief (>30% improvement in pain lasting from 2–12 weeks) over a 12-week treatment period was 43% in the capsaicin 8% patch group and 34% in the control group, a statistically significant difference.
The 8% capsaicin patch provides a localized therapy with effects lasting up to 12 weeks after a single 60-minute application. Safety and efficacy of capsaicin 8% have been demonstrated in open-label trials for up to 48 weeks. In a direct comparison, the 8% capsaicin patch has been shown to be noninferior to pregabalin in the control of neuropathic pain, but with a faster onset of analgesia and fewer systemic side effects.
A 2013 Cochrane database systematic review of six randomized trials compared single application of high-dose (8%) capsaicin patch to low-dose (0.04%) patch in 2,073 adult patients with chronic neuropathic pain. Four of these trials involved 1,272 patients with postherpetic neuralgia. At 8 and 12 weeks, capsaicin 8% patch therapy was associated with an increase in patients' reports of feeling much or very much better, with numbers needed to treat of 8.8 and 7, respectively. Serious adverse effects were not more frequent with high-dose treatment than control.
4.2 Neuropathic and Musculoskeletal Pain: Low-Concentration Topical Preparations
Lower-concentration topical preparations have also been evaluated. A systematic review reported that the relative benefit from topical capsaicin 0.075% compared with placebo was 1.4 (95% confidence interval 1.2 to 1.7) with a number needed to treat of 5.7 (4.0 to 10.0). Three double-blind placebo-controlled trials (368 patients) were pooled for musculoskeletal conditions, with relative benefit from topical capsaicin 0.025% or plaster compared with placebo of 1.5 (1.1 to 2.0) and a number needed to treat of 8.1 (4.6 to 34).
Although topically applied capsaicin has moderate to poor efficacy in the treatment of chronic musculoskeletal or neuropathic pain, it may be useful as an adjunct or sole therapy for a small number of patients who are unresponsive to, or intolerant of, other treatments. Based on 313 patients in 4 studies, capsaicin resulted in a statistically significant improvement in neuropathic pain at 4 weeks (RR 1.4, 95% CI: 1.1, 1.7); the corresponding number needed to treat was 6.4 (95% CI: 3.8, 21).
4.3 Postherpetic Neuralgia: Topical Evidence
High-concentration topical capsaicin used to treat postherpetic neuralgia, HIV neuropathy, and painful diabetic neuropathy generated more participants with moderate or substantial levels of pain relief than control treatment using a much lower concentration of capsaicin. A systematic review and meta-analysis of six double-blinded, randomized, placebo- or vehicle-controlled trials in postherpetic neuralgia reported that the difference in mean percentage change in numeric pain rating scale score ranged from −31 to −4.3, demonstrating high efficacy of topical capsaicin application and implying that capsaicin could result in pain reduction. The incidence of side effects from using topical capsaicin is consistently higher in all included studies, but topical capsaicin is a promising treatment option for specific patient groups or certain neuropathic pain conditions such as postherpetic neuralgia.
4.4 Osteoarthritis Pain
Osteoarthritis (OA) affects hundreds of millions of people worldwide. A systematic review and meta-analysis critically appraised the efficacy and safety of topical capsaicin in reducing OA pain. The eligibility criteria included randomized controlled trials (RCTs) evaluating topical capsaicin in OA patients, using standard Cochrane methods. Eight double-blind RCTs involving 498 patients were included. Topical capsaicin may reduce OA pain at follow-ups of up to 3 months. Limitations include short study durations, small sample sizes, high heterogeneity, and overall low-to-very-low certainty of the evidence. Topical capsaicin might be recommended for short-term management of pain in OA patients intolerant to nonsteroidal anti-inflammatory drugs.
4.5 Metabolic Effects: Weight Management and Obesity
Numerous epidemiological and animal studies have indicated that capsaicin, as a TRPV1 agonist, may represent a potential strategy to treat obesity. Although much of the effect is believed to be caused by stimulation of the TRPV1 receptor, the mechanism of action is not presently fully understood. Meta-analyses of clinical trials also show modest but significant increases in resting metabolic rate and fat oxidation, particularly in individuals with overweight or obesity.
Activation of TRPV1 by capsaicin can attenuate abnormal glucose homeostasis by stimulating insulin secretion and increasing GLP-1 levels. Evidence in the weight-loss domain, while present from clinical trials, remains preliminary. Study heterogeneity, small sample sizes, and short durations limit the strength of conclusions that can be drawn for routine clinical application.
4.6 Lipid-Lowering Effects in Metabolic Syndrome
A systematic review and meta-analysis of nine randomized controlled trials including 461 patients with metabolic syndrome found that capsaicin significantly decreased total cholesterol (WMD = −0.48, 95% CI: −0.63 to −0.34, I² = 0.00%) and LDL-C (WMD = −0.23, 95% CI: −0.45 to −0.02, I² = 68.27%). No significant effects of capsaicin were found on triglycerides or HDL-C. Subgroup analyses indicated that sex and intervention period were sources of heterogeneity. These findings are considered preliminary, and the high heterogeneity for LDL-C effects warrants cautious interpretation.
4.7 Cardiovascular Effects
Capsaicin, the principal bioactive compound derived from chili peppers, has attracted growing interest as a multitarget modulator of the complex pathophysiology underlying cardiometabolic syndrome. Accumulating evidence indicates that capsaicin confers cardiometabolic protection predominantly through TRPV1-mediated signaling, while additional TRPV1-independent mechanisms may also contribute. Recent studies highlight the importance of a capsaicin–gut microbiota axis, whereby capsaicin reshapes microbial composition, modulates bile acid and short-chain fatty acid signaling, and reinforces intestinal barrier integrity, thereby exerting systemic metabolic and cardiovascular benefits. Despite compelling mechanistic and preclinical evidence, translation to clinical application remains limited by variability in effective dosing, bioavailability, and interindividual differences in gut microbiota composition.
4.8 Anticancer Effects: Predominantly Preclinical
Recent studies have shown that capsaicin has profound antineoplastic effects in several types of human cancers. However, the applications of capsaicin as a clinically viable drug are limited by its unpleasant side effects, such as gastric irritation, stomach cramps, and burning sensation.
Assessment of the eligible literature revealed that the potential of capsaicin for mitigating cancer mainly entails its chemopreventive effects, which were often linked to its ability to exert multi-biological effects such as anti-mutagenic, antioxidant, and anti-inflammatory activities. Several convergent studies show that capsaicin displays robust cancer activity, suppressing the growth, angiogenesis, and metastasis of several human cancers. Despite its potent cancer-suppressing activity, the clinical applications of capsaicin as a viable anti-cancer drug have remained problematic due to its poor bioavailability and aqueous solubility properties.
Emerging evidence shows that capsaicin displays anticancer activity in several human cancers, both in cell culture and mice models. However, an overwhelming majority of research papers show that capsaicin displays growth-inhibitory effects in human cancer cells, but a few studies have suggested that capsaicin promotes the survival and growth of breast, colon, and skin cancers. It must be emphasized that as of current evidence, anticancer effects of capsaicin have been demonstrated primarily in preclinical (cell culture and animal) models; no established human clinical trial evidence yet supports its use as an anticancer therapy.
4.9 Gastrointestinal Effects
Capsaicin has demonstrated potential as a treatment for gastrointestinal conditions, in addition to cardiovascular, oncological, and dermatological conditions. TRPV1 is also upregulated in several human pathological conditions including vulvodynia, GI inflammation, Crohn's disease, and ulcerative colitis. The precise clinical evidence for capsaicin in GI conditions remains mixed and largely derived from observational or small trials; this is an active area of preclinical and clinical investigation.
5. Body Systems and Health Areas Associated with Capsaicin
Capsaicin has applications in pain management, cardiovascular health, anti-inflammatory effects, and metabolic regulation. More specifically, the body systems implicated in capsaicin's activity include:
- Peripheral and central nervous system: The TRPV1 channel, which is involved in a wide range of neuronal processes, is expressed in peripheral and central branches of capsaicin-sensitive nociceptive neurons, sensory ganglia, the spinal cord, and different brain regions in neuronal cell bodies, dendrites, astrocytes, and pericytes.
- Musculoskeletal system: Topical capsaicin preparations are used for arthritis and musculoskeletal pain, supported by multiple RCTs and systematic reviews, although evidence quality is generally moderate to low.
- Cardiovascular and metabolic systems: Cardiometabolic syndrome is a multifactorial disorder characterized by the clustering of central obesity, insulin resistance, atherogenic dyslipidemia, hypertension, and chronic low-grade inflammation, collectively predisposing individuals to type 2 diabetes and increased cardiovascular morbidity and mortality. Capsaicin has been studied in this context with modest evidence from RCTs.
- Gastrointestinal system: TRPV1 signaling is present throughout the gut wall; capsaicin has been investigated for its effects on GI motility, mucosal protection, and gut microbiota.
- Integumentary system (skin): Topical capsaicin is used for dermatological applications including psoriasis-associated itch, and is a common ingredient in analgesic skin preparations.
- Oncological: Preclinical research has identified potential chemopreventive roles for capsaicin across multiple cancer types. Capsaicin has demonstrated potential antiproliferative effects in cancer cells. It operates by inducing programmed cell death, regulating the expression of transcription factors, halting cell cycle progression, and influencing growth signal transduction pathways.
6. Dosage Forms and Dosages Reported in Studies
Topical Preparations
Topical capsaicin is available as patches, creams, films, liquids, and lotions, all applied to the skin. The dosage form includes topical cream (0.025%; 0.033%; 0.035%; 0.075%; 0.1%; 0.25%), topical film (0.025%), topical liquid (0.025%), topical lotion (0.025%; 0.035%), and topical system (patches, 8%).
For the prescription-strength 8% patch: capsaicin 8% patches are applied to the most painful areas of healthy skin and allowed to remain for 60 minutes. Treatment can be repeated every 90 days if the pain persists or returns. The maximum recommended human dose is 716 mg capsaicin per day (4 patches containing 179 mg/patch).
For lower-concentration OTC preparations: for topical dosage forms (cream, gel, lotion, or ointment), the general instruction for adults is to apply 3 or 4 times a day and rub it in well.
Systemic/Oral Administration in Research
In metabolic and lipid research, capsaicin has been administered orally in various trial doses. The specific doses vary considerably across studies, and no single standardized oral dose has been established for supplementation purposes. Longer-term capsinoid supplementation has been shown to increase brown adipose tissue vascular density and resting energy expenditure in healthy middle-aged adults.
7. Safety Considerations and Notable Interactions
Local Adverse Effects (Topical)
The more common potential adverse reactions and events with topical patch administration include local erythema, local pain, local pruritus, local edema, local swelling, local dryness, hypertension, papules, pruritus, nausea, vomiting, nasopharyngitis, sinusitis, and bronchitis. The more rare complications include abnormal skin odor, cough, dizziness, dysgeusia, headaches, hypesthesia, peripheral edema, peripheral sensory neuropathy, and throat irritation.
The most common adverse drug reactions occurring with the 8% capsaicin patch are application site erythema (63%) and application site pain (42%). Some patients experienced transient increases in blood pressure during application. Topical application of capsaicin can be painful, particularly for treatments containing the relatively high capsaicin concentrations necessary to deliver an effective dose. The 8% patch has significant adverse effects in some patients that include severe pain during localized application, erythema, and pruritus.
Around one third of patients experienced local adverse events with capsaicin, which would not have been the case with placebo.
Systemic and Ingestion-Related Adverse Effects
Without proper instruction on use, capsaicin can cause burning or stinging pain to the skin and, if ingested in large amounts by adults or small amounts by children, can produce nausea, vomiting, abdominal pain, and burning diarrhea. Eye exposure produces intense tearing, pain, conjunctivitis, and blepharospasm. The administration of capsaicin is associated with adverse side effects such as gastrointestinal cramps, stomach pain, nausea, and diarrhea and vomiting.
Cardiovascular Caution
The treated area may be sensitive to heat for several days after patch application (e.g., from hot water, direct sunlight, vigorous exercise). Caution is advised in patients with uncontrolled hypertension or history of cerebrovascular events.
Special Populations
Appropriate studies have not been performed on the relationship of age to the effects of capsaicin in the pediatric population; safety and efficacy have not been established in children. In controlled clinical trials of the Qutenza 8% patch in neuropathic pain associated with postherpetic neuralgia, 75% of patients were 65 years and older and 43% were 75 years and older. Safety and effectiveness were similar in geriatric patients and younger patients. No evidence of malformations was observed when capsaicin was topically administered daily to pregnant rats and rabbits during organogenesis at doses of up to 11- and 37-times, respectively, the maximum recommended human dose.
Known Drug Interactions
Formal drug interaction databases classify topical capsaicin as having no listed severe, serious, or moderate interactions with other drugs at current evidence levels. However, caution is specifically advised in patients with uncontrolled hypertension or a history of cerebrovascular events. Systemic absorption from topically applied capsaicin preparations is low, limiting pharmacokinetic interaction potential, but systemic use may involve broader interaction considerations not yet fully characterized in clinical literature.
High-Dose and Prescription Administration Requirements
The 8% capsaicin patch must be administered by a physician or under the close supervision of a physician. Prior to application, the affected area should be pretreated with a topical anesthetic to reduce application site pain. Some patients may require systemic analgesics during and after treatment for treatment-associated pain.
References
Go back